a phase 4 study of efficacy and safety of apremilast in subjects with moderate plaque psoriasis.

Conditions: Parapsoriasis

Summary: this study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (bid) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week placebo controlled phase and then upto 1 year in the extension phase of the trial.

this is a phase 4, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast in subjects with moderate plaque psoriasis. 221 participants were randomized 2 (apremilast):1 (placebo) at approximately 25 sites in the united states. those randomized to the apremilast treatment group received apremilast 30 mg tablets orally twice daily for 52 weeks. those randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally twice daily (bid) for 16 weeks. beginning week 16, those initially randomized to placebo were switched to receive apremilast 30 mg bid for an additional 36 weeks (52 weeks total). study enrolled adult patients with stable moderate plaque psoriasis, who are naïve to systemic psoriasis treatments.

Eligibility criteria:
inclusion criteria: 1. males or females, ≥ 18 years of age at the time of signing the informed consent document. 2. understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. 3. able to adhere to the study visit schedule and other protocol requirements. 4. diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the informed consent. 5. have moderate plaque psoriasis at screening and baseline as defined by 1. bsa (body surface area)5% to 10% and 2. spga (physician's global assessment) 3 (moderate) based on a 0 to 5 point scale 6. must be in general good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, and clinical laboratories. 7. no prior exposure to systemic treatments or biologics for the treatment of psoriatic arthritis, psoriasis, or any other indication that could impact the assessment of psoriasis. 8. females of childbearing potential (fcbp)must have a negative pregnancy test at screening and baseline. while on investigational product and for at least 28 days after taking the last dose of investigational product, fcbp who engage in activity in which conception is possible must use one of the approved contraceptive§ options described below: option 1: any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (iud); tubal ligation; or partner's vasectomy; or option 2: male or female condom (latex condom or nonlatex condom not made out of natural \[animal\] membrane \[for example, polyurethane\]) plus one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. 9. male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom not made out of natural \[animal\] membrane \[for example, polyurethane\]) while on investigational product and for at least 28 days after the last dose of investigational product exclusion criteria: 1. other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic,immunologic disease, or other major disease that is currently uncontrolled. 2. any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study. 3. any condition, including other inflammatory diseases or dermatologic conditions, which confounds the ability to interpret data from the study, including other types of psoriasis (ie, erythrodermic, guttate, inverse, or pustular psoriasis), other than plaque psoriasis. 4. prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent. 5. pregnant or breast feeding. 6. active substance abuse or a history of substance abuse within 6 months prior to signing the informed consent. 7. malignancy or history of malignancy, except for: 1. treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; 2. treated (ie, cured) cervical intraepithelial neoplasia (cin) or carcinoma in situ of the cervix with no evidence of recurrence within 5 years of signing the informed consent. 8. topical therapy within 2 weeks of randomization (including, but not limited to, topical corticosteroids, retinoids or vitamin d analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol). use of phototherapy within 4 weeks prior to randomization. 9. use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer). 10. prolonged sun exposure or use of tanning booths, which may confound the ability to interpret data from the study. 11. prior treatment with apremilast.

Keywords: parapsoriasis plaque psoriasis cc-10004 apremilast moderate plaque psoriasis safety